Celcuity, Inc. announced that the first patient has been dosed in its Phase Ib/II study evaluating gedatolisib in combination with Nubeqa®, an approved androgen receptor inhibitor, for the treatment of patients with metastatic castration resistant prostate cancer.
[Celcuity, Inc. (GlobeNewswire, Inc.)]